Restricted use for spinal tumour treatment:
This article was originally published in Clinica
Interpore Cross International has received permission from the US FDA to sell a limited number of its expandable titanium spacers for replacing spinal segments under a humanitarian device exemption (HDE). The Telescopic Plate Spacer can be used where patients have had one of two spine vertebral bodies removed due to cancer. The Irvine, California-based company said the device is designed to allow insertion of bone graft material, adding that there are no other FDA-cleared devices that function in the same way. An HDE allows companies to market products for treating conditions that affect fewer than 4,000 people.
You may also be interested in...
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.